9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Intrapleural Gene Transfer for Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 13Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: UPCC 18508; 808806|P01CA066726Study First Received: September 29, 2010Last Updated: September 21, 2015Estimated Primary Completion Date: May 2015Primary Outcome Measures:To analyze gene transfer with two does separated by three-day intervalSponsors and Collaborators:Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01212367...

Continue reading

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 13Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02839|PHII 67|N01CM62209Study First Received: August 16, 2006Last Updated: December 17, 2014Estimated Primary Completion Date: March 2009Primary Outcome Measures:Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee|Overall Survival|Time to Progression|Toxicity Profile as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.|Apoptosis by TUNEL Assay|Histone Acetylation by IHC and Western BlottingSponsors and Collaborators:National Cancer Institute (NCI)Result...

Continue reading

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

ConditionMALIGNANT PLEURAL MESOTHELIOMAEstimated Enrollment: 121Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Cohort|Time Perspective: RetrospectiveStudy ID Numbers: ONC/OSS-04/2008Study First Received: March 23, 2009Last Updated: December 1, 2014Estimated Primary Completion Date: December 2011Primary Outcome Measures:Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line|Evaluate retrospectively the correlation between gene expression and polymorphisms in candidate genes and array-CGH data, immunohistochemistry data, and clinical data.Sponsors and Collaborators:Istituto Clinico HumanitasResult Received: No...

Continue reading

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 51Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2009-00126|N01CM17102|CDR0000463521|14203BStudy First Received: March 29, 2006Last Updated: July 25, 2014Estimated Primary Completion Date: September 2010Primary Outcome Measures:Objective Response Rate, Complete (CR) or Partial (PR) Response|Changes in Laboratory Correlates|Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and ToxicitySponsors and Collaborators:National Cancer Institute (NCI)Result Received: July 1, 2013Website Link: https://ClinicalTrials.gov/show/NCT00309946...

Continue reading

Gefitinib in Treating Patients With Malignant Mesothelioma

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 40Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02414|CLB-30101|U10CA031946|CDR0000068938Study First Received: October 11, 2001Last Updated: January 15, 2013Estimated Primary Completion Date: February 2006Primary Outcome Measures:Percentage of patients who remain failure-free|Tumor response rate|Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0|Overall survival|Failure-free survival within patient subgroups defined in terms of epidermal growth factor receptor (EGFR) overexpression and cyclooxygenase-2 (COX-2) expressionSponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study...

Continue reading

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 55Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02466|SWOG-S0218|U10CA032102|CDR0000069360Study First Received: June 6, 2002Last Updated: January 23, 2013Estimated Primary Completion Date: June 2007Primary Outcome Measures:Overall survival rate|RECIST response rate|Association between EGFR expression with survival and responseSponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00039182...

Continue reading

S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

ConditionAdvanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous MesotheliomaEstimated Enrollment: 54Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02902|S0509|U10CA032102|CDR0000446178Study First Received: October 20, 2005Last Updated: September 21, 2015Estimated Primary Completion Date: April 2010Primary Outcome Measures:Overall Response Rate|Overall Survival|Progression-free Survival|Disease Control Rate|Objective Response Rate Per Modified RECIST for Pleural Tumors|Adverse Event Rates|Adverse EventsSponsors and Collaborators:National Cancer Institute (NCI)Result Received: October 30, 2012Website Link: https://ClinicalTrials.gov/show/NCT00243074...

Continue reading

Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma

ConditionMalignant Mesothelioma|Metastatic CancerEstimated Enrollment: 196Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: P00804|PAPWORTH-MESOVATS|PAPWORTH-P00804|EU-20901|ISRCTN34321019Study First Received: January 13, 2009Last Updated: June 27, 2013Estimated Primary Completion Date: February 2013Primary Outcome Measures:Survival at 1 year after treatment|Control of pleural effusion|Complications, including need for more surgery, persistent air leak requiring pleural intubation for > 10 days, and hospital stay for > 12 days|Symptoms and quality of life as assessed by the EuroQol questionnaire|Length of hospital stay|Exercise tolerance|Cost to the health service, in terms of resources used for...

Continue reading

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

ConditionPart A and B: Advanced Solid Malignancies|Part C: Malignant MesotheliomaEstimated Enrollment: 73Age Group: 20 Years to 130 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Masking: No masking|Primary Purpose: OtherStudy ID Numbers: D4880C00010Study First Received: May 14, 2014Last Updated: April 12, 2017Estimated Primary Completion Date: January 27, 2017Primary Outcome Measures:Adverse eventSponsors and Collaborators:AstraZenecaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT02141347...

Continue reading

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

ConditionLung Cancer|Malignant MesotheliomaEstimated Enrollment: 20Age Group: 20 Years to 70 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: CDR0000067177|RPCI-DS-96-25Study First Received: November 1, 1999Last Updated: March 3, 2011Estimated Primary Completion Date: June 1998Primary Outcome Measures:Sponsors and Collaborators:Roswell Park Cancer InstituteResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00003974...

Continue reading